A J Mitchell1, M Shiri-Feshki. 1. Liaison Psychiatry, Leicester Partnership Trust and University of Leicester, Leicester, UK. alex.mitchell@leicspart.nhs.uk
Abstract
OBJECTIVE: To quantify the risk of developing dementia in those with mild cognitive impairment (MCI). METHOD: Meta-analysis of inception cohort studies. RESULTS: Forty-one robust cohort studies were identified. To avoid heterogeneity clinical studies, population studies and clinical trials were analysed separately. Using Mayo defined MCI at baseline and adjusting for sample size, the cumulative proportion who progressed to dementia, to Alzheimer's disease (AD) and to vascular dementia (VaD) was 39.2%, 33.6% and 6.2%, respectively in specialist settings and 21.9%, 28.9% and 5.2%, respectively in population studies. The adjusted annual conversion rate (ACR) from Mayo defined MCI to dementia, AD and VaD was 9.6%, 8.1% and 1.9%, respectively in specialist clinical settings and 4.9%, 6.8% and 1.6% in community studies. Figures from non-Mayo defined MCI and clinical trials are also reported. CONCLUSION: The ACR is approximately 5-10% and most people with MCI will not progress to dementia even after 10 years of follow-up.
OBJECTIVE: To quantify the risk of developing dementia in those with mild cognitive impairment (MCI). METHOD: Meta-analysis of inception cohort studies. RESULTS: Forty-one robust cohort studies were identified. To avoid heterogeneity clinical studies, population studies and clinical trials were analysed separately. Using Mayo defined MCI at baseline and adjusting for sample size, the cumulative proportion who progressed to dementia, to Alzheimer's disease (AD) and to vascular dementia (VaD) was 39.2%, 33.6% and 6.2%, respectively in specialist settings and 21.9%, 28.9% and 5.2%, respectively in population studies. The adjusted annual conversion rate (ACR) from Mayo defined MCI to dementia, AD and VaD was 9.6%, 8.1% and 1.9%, respectively in specialist clinical settings and 4.9%, 6.8% and 1.6% in community studies. Figures from non-Mayo defined MCI and clinical trials are also reported. CONCLUSION: The ACR is approximately 5-10% and most people with MCI will not progress to dementia even after 10 years of follow-up.
Authors: Michelle M Mielke; Ozioma C Okonkwo; Kenichi Oishi; Susumu Mori; Sarah Tighe; Michael I Miller; Can Ceritoglu; Timothy Brown; Marilyn Albert; Constantine G Lyketsos Journal: Alzheimers Dement Date: 2012 Impact factor: 21.566
Authors: Wendy S Ramratan; Laura A Rabin; Cuiling Wang; Molly E Zimmerman; Mindy J Katz; Richard B Lipton; Herman Buschke Journal: J Int Neuropsychol Soc Date: 2012-01-23 Impact factor: 2.892
Authors: Klaus H Fritzsche; Bram Stieltjes; Sarah Schlindwein; Thomas van Bruggen; Marco Essig; Hans-Peter Meinzer Journal: Int J Comput Assist Radiol Surg Date: 2010-05-04 Impact factor: 2.924
Authors: Mary Ganguli; Ching-Wen Lee; Beth E Snitz; Tiffany F Hughes; Eric M McDade; Chung-Chou H Chang Journal: Alzheimer Dis Assoc Disord Date: 2014 Apr-Jun Impact factor: 2.703
Authors: Tanis J Ferman; Glenn E Smith; Kejal Kantarci; Bradley F Boeve; V Shane Pankratz; Dennis W Dickson; Neill R Graff-Radford; Zbigniew Wszolek; Jay Van Gerpen; Ryan Uitti; Otto Pedraza; Melissa E Murray; Jeremiah Aakre; Joseph Parisi; David S Knopman; Ronald C Petersen Journal: Neurology Date: 2013-11-08 Impact factor: 9.910
Authors: Peng Yu; Jia Sun; Robin Wolz; Diane Stephenson; James Brewer; Nick C Fox; Patricia E Cole; Clifford R Jack; Derek L G Hill; Adam J Schwarz Journal: Neurobiol Aging Date: 2013-10-03 Impact factor: 4.673